Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate Plc (NYSE: CLVT) has priced concurrent offerings of 38,461,538 ordinary shares at $26.00 each and 12,500,000 5.25% Series A Mandatory Convertible preferred shares at $100 each. The offerings are expected to close on June 14, 2021. The company anticipates net proceeds of approximately $723.8 million from the ordinary shares and $1.208 billion from the preferred shares. The funds will primarily finance the pending acquisition of ProQuest, announced on May 17, 2021. The convertible preferred shares will convert into ordinary shares on June 1, 2024, if not redeemed earlier.
Clarivate Plc (NYSE: CLVT) announced on June 8, 2021, the proposed offerings of $750 million in ordinary shares and $1.25 billion in Series A Mandatory Convertible preferred shares. These offerings, which total $2 billion, aim to finance its pending acquisition of ProQuest. The completion of either offering is independent and subject to market conditions. If the acquisition does not proceed, proceeds will be used for general corporate purposes. The convertible preferred shares will convert into ordinary shares on June 1, 2024.
Clarivate Plc (NYSE:CLVT) has launched the COVID-19 Vaccine Availability and Medtech Impact Report, forecasting vaccination rates across countries in 2021. The report indicates that vaccine acceptance varies by region, with rates of 94% in Malaysia and 71% in the U.S. It highlights the importance of vaccination in recovering healthcare markets post-pandemic, particularly for Ambulatory Surgery Centers (ASCs) which showed higher utilization rates. The predictive analysis leverages real-world data to aid healthcare stakeholders in planning and decision-making.
Clarivate Plc (NYSE: CLVT) has announced a commercial partnership with Explore IP to integrate Derwent™ patent data into its platform. This collaboration aims to enhance the searchability of intellectual property data, enabling businesses and innovators to identify and understand patents held by Canadian public sector institutions. The partnership will facilitate licensing opportunities and foster innovation by providing access to authoritative patent information. This integration will support Canadian entrepreneurs and significantly improve the marketability of public sector technologies.
On May 26, 2021, Clarivate Plc (NYSE: CLVT) announced that its Executive Chairman and CEO, Jerre Stead, along with CFO Richard Hanks, will present at three upcoming virtual investor conferences in June 2021. The conferences include: William Blair's 41st Annual Growth Stock Conference on June 2 at 10:00 am CT, Baird's 2021 Global Consumer, Technology & Services Conference on June 8 at 12:15 pm ET, and Stifel's 2021 Virtual Cross Sector Insight Conference on June 10 at 8:00 am ET. Live webcasts will be available for each event.
On May 18, 2021, Clarivate Plc (NYSE:CLVT) announced a strategic partnership with Alt Legal, Inc. to integrate CompuMark™ international trademark data into Alt Legal's platform. This collaboration aims to enhance Alt Legal's offerings by providing access to 186 trademark databases globally. The integration will allow users to receive updates on trademark filings, streamline workflows, and minimize human error. Alt Legal is responding to client demand for broader international capabilities, positioning itself as a leading docketing solution for global trademark management.
Clarivate (NYSE: CLVT) has agreed to acquire ProQuest for $5.3 billion, enhancing its position as a leading provider of research intelligence solutions. The deal includes $4 billion in cash and $1.3 billion in equity, with expected closing in Q3 2021. ProQuest serves over 25,000 institutions globally, and this acquisition will expand Clarivate’s data offerings significantly. Financially, the transaction is projected to be accretive to earnings, with anticipated cost synergies exceeding $100 million within 15-18 months, paired with substantial cash tax savings.
Clarivate Plc (NYSE: CLVT) will present at the Barclays Americas Select Franchise Conference on May 19, 2021, at 1:00 PM Eastern Time. The presentation will feature Executive Chairman and CEO Jerre Stead and CFO Richard Hanks. A live webcast will be available on the Investor Relations section of Clarivate's website, with a replay accessible for 30 days post-event. Clarivate is dedicated to accelerating innovation through actionable insights and solutions in science and intellectual property.
Clarivate reaffirmed its 2021 outlook for key financial metrics including Adjusted revenues, Adjusted EBITDA, and Adjusted free cash flow. The company also filed its Form 10-Q for Q1 2021, reporting a net loss of $24.0 million ($0.04 per diluted share), an improvement from a loss of $129.6 million in Q1 2020. Adjusted net income rose to $88.4 million ($0.14 per diluted share) versus $25.5 million ($0.07 per diluted share) year-over-year. Additionally, adjustments were made to the classification of certain warrants as liabilities, impacting financial statements without altering reported revenues or cash flows.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
